A Phase 2 clinical trial is now underway to evaluate sofosbuvir (Sovaldi) plus ribavirin for children and adolescents, ages 3-17 years, with hepatitis C virus genotypes 2 or 3. Another study will follow to test the forthcoming sofosbuvir/ledipasir coformulation in pediatric patients.
Three broadly neutralizing antibodies delivered by a viral vector blocked hepatitis C virus (HCV) infection of hepatocytes (liver cells) in a laboratory culture model and appeared to cure infection in modified mice carrying human liver tissue, researchers reported in the September 17 edition of Science Translational Medicine.
People coinfected with HIV and tuberculosis (TB) who go onto develop immune reconstitution inflammatory syndrome (IRIS) while on antiretroviral therapy (ART) have a pre-ART immunological profile that is easily distinguishable from those who are at risk of early mortality despite being treated for both HIV and TB, according to a presentation at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this month in Washington, DC.
Cal Cohen of the Community Research Initiative of New England sat down with HIVandHepstitis.com to offer his summary of some of the highlights of HIV treatment and prevention research presented at the 20th International AIDS Conference last month in Melbourne, Australia.